Kinobeads(TM) Technology to Identify a New Generation of Drug Candidates
for Inflammatory Diseases
LONDON and CAMBRIDGE, England and PHILADELPHIA and HEIDELBERG, Germany, September 10 /PRNewswire/ -- Cellzome Inc. and GlaxoSmithKline (LSE & NYSE: GSK) announce the signing of a worldwide strategic alliance to discover, develop and market novel kinase-targeted therapeutics to treat inflammatory diseases.
The alliance gives GSK access to Cellzome's significant expertise in identifying and developing selective kinase inhibitors and its proprietary Kinobeads(TM) technology which, by screening compounds in a physiological setting, is designed to improve the predictability of these drug candidates' performance in clinical testing. Kinases are key molecular switches in cellular signaling events with a central role in many inflammatory responses and selective inhibitors offer a different approach to therapeutic intervention in diseases such as rheumatoid arthritis or multiple sclerosis.
Under the agreement GSK has exclusive options to license drug
candidates from Cellzome's kinase programs directed against four identified
targets, and three additional targets to be jointly identified by both
parties. In the alliance, Cellzome will utilize its proprietary
Kinobeads(TM) technology to discover novel small molecule inhibitors of
these targets, and then will develop the most promising product candidates
through to completion of a clinical proof of concept trial, unless GSK
elects to exercise its option earlier. Cellzome is eligible to receive
success-based milestones from GSK as product candidates are advanced. Upon
Cellzome's achievement of clinical proof of concept for a product candidate
for a particular kinase target, GSK would have an exclusive option to
license all product candidates from that program. GSK would then assume
full responsibility for further clinical development and commercialization
on a worldwide basis. Ce
|SOURCE Cellzome Inc.|
Copyright©2008 PR Newswire.
All rights reserved